不对称催化氢化反应是合成手性分子的重要方法之一，而C2对称性配体选择是设计此类反应的关键。

DuPHOSTM是一种新颖的富电子C2对称性手性双膦杂环戊烷配体，具有合适的立体位阻效应。相对于其他类型的手性双膦配体，美国STREM工厂研发生产的DuPHOSTM和BPE配体，在烯酰胺、2-烷基琥珀酸、羟基酯、开链烯醇酯、酮等类型底物的不对称催化氢化反应中显示出了极高的对映体选择性，因此被广泛应用于精细化工、医药行业。

2008年百灵威与STREM正式签署战略合作协议，全权负责STREM在中国市场的产品销售、技术应用与支持等各项业务。百灵威始终秉承“资源共享、共同发展”之理念，一如既往地为中国化学行业广大科研和生产用户提供品质卓越的有机金属、配体、催化剂等产品及服务！

Sold in collaboration with Chirotech for research purposes only.1



Versatility of the DuPhos and BPE Ligand Systems in Asymmetric Catalytic Hydrogenation
1. For reviews see:- (a) M.J. Burk, Acc. Chem. Res. 2000, 33, 363. (b) I.C. Lennon, C.J. Pilkington, Synthesis, 2003, 1639.
2. M.J. Burk, J.E. Feaster, W.A. Nugent, R.L. Harlow, J. Am. Chem. Soc., 1993, 115, 10125.
3. M.J. Burk, J.G. Allen, W.F. Kiesman, J. Am. Chem. Soc., 1998, 120, 657.
4. A. Robinson, H.-Y. Li, J.E. Feaster, Tetrahedron Lett. 1996, 37, 8321.
5. M.J. Burk, J.R. Lee, Y. Wang, J. Am. Chem. Soc., 1996, 118, 5142.
6. a) M..J. Burk, G. Casy, N.B. Johnson, J. Org. Chem. 1998, 63, 6084.
b) P. Harrison, G. Meek, Tetrahedron Lett., 2004, 45, 9277.
7. E.A. Broger, Y. Crameri, R. Schmid, T. Siegrfried, Hoffman-La Roche, EP 0691 325 A, 1996.
8. M.J. Burk, F. Bienewald, M. Harris, A. Zanotti-Gerosa, Angew. Chem. Int. Ed. Engl, 1998, 37, 1931.
9. C.J. Cobley, I.C. Lennon, C. Praquin, A. Zanotti-Gerosa, R.B. Appell, C.T. Goralski, A.C. Sutterer, Org. Process Res. Dev.
2003, 7, 407.
10. M.J. Burk, F. Bienewald, S. Challenger, A. Derrick, J.A. Ramsden, J. Org. Chem. 1999, 64, 3290.
11. M.J. Burk, P.D. de Koning, T.M. Grote, M.S. Hoekstra, G. Hoge, R.A. Jennings, W.S. Kissel, T.V. Le, I.C. Lennon, T.A.
Mulhern, J.A. Ramsden,R.A. Wade, J. Org. Chem. 2003, 68, 5731.
12. N.W. Boaz, Tetrahedron Lett., 1998, 39, 5505.
13. M.J. Burk, C.S. Kalberg, A. Pizzano, J. Am. Chem. Soc., 1998, 120, 4345.
14. M.J. Burk, N.B. Johnson, J. Lee, Tetrahedron Lett. 1999, 40, 6685.
15. a) M.J. Burk, M.F. Gross, J.P. Martinez, J. Am. Chem. Soc. 1995, 117, 9375.
b) G.J. Roff, R.C. Lloyd, N.J. Turner, J. Am. Chem. Soc. 2004, 126, 4098.
16. M.E.B. Smith, M.C. Lloyd, N. Derrien, R.C. Lloyd, S.J.C. Taylor, D.A. Chaplin, G. Casy, R. McCague, Tetrahedron: Asymme
try 2001, 12, 703.
17. H-J. Drexler, J. You, S. Zhang, C. Fischer, W. Baumann, A. Spannenberg, D. Heller, Org. Process Res. Dev. 2003, 7, 355.

Phosphorus
15-0097 (-)-1,2-Bis((2R,5R)-2,5-diethylphospholano)benzene,98+% (R,R)-Et-DUPHOS
[136705-64-1] 100mg
500mg
2g 15-0098 (+)-1,2-Bis((2S,5S)-2,5-diethylphospholano)benzene, 98+%(S,S)-Et-DUPHOS
[136779-28-7] 100mg
500mg
2g
15-0101 (+)-1,2-Bis((2R,5R)-2,5-diethylphospholano)ethane, 98+%(R,R)-Et-BPE
[136705-62-9] 100mg
500mg 15-0102 (-)-1,2-Bis((2S,5S)-2,5-diethylphospholano)ethane,98+%(S,S)-Et-BPE
[136779-27-6] 100mg
500mg
15-0096 (-)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)benzene,98+%(R,R)-Me-DUPHOS
[147253-67-6] 100mg
500mg
2g 15-0092 (+)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)benzene,98+% (S,S)-Me-DUPHOS
[136735-95-0] 100mg
500mg
2g
15-0104 (+)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)ethane,98+%(R,R)-Me-BPE
[129648-07-3] 100mg
500mg
2g 15-0105 (-)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)ethane, 98+% (S,S)-Me-BPE
[136779-26-5] 100mg
500mg
2g
15-0410 (+)-1,2-Bis((2R,5R)-2,5-di-i-propylphospholano)benzene,98+%(R,R)-i-Pr-DUPHOS
[136705-65-2] 100mg
500mg
2g 15-0411 (-)-1,2-Bis((2S,5S)-2,5-di-i-propylphospholano)benzene,98+% (S,S)-i-Pr-DUPHOS
[147253-69-8] 100mg
500mg
2g
15-0473 (-)-1,2-Bis((2R,5R)-2,5-diphenylphospholano)ethane, min.98%(R,R)-Ph-BPE
[528565-79-9] 100mg
500mg
2g 15-0474 (+)-1,2-Bis((2S,5S)-2,5-diphenylphospholano)ethane,min.98%(S,S)-Ph-BPE
[824395-67-7] 100mg
500mg
2g


Rhodium
96-4730 (R,R)-Duphos and BPE Rhodium Catalyst Kit Components availabe for individual sale.Contains 100mg of the following 7 items: 1kit 96-4731 (S,S)-Duphos and BPE Rhodium Catalyst Kit Components availabe for individual sale.Contains 100mg of the following 7 items: 1kit
45-0148 (-)-1,2-Bis((2R,5R)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium(I) tetrafluoroborate,98+%(R,R)-Et-DUPHOS-Rh
[228121-39-9] 100mg
500mg
2g 45-0149 (+)-1,2-Bis((2S,5S)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium(I) tetrafluoroborate,98+% (S,S)-Et-DUPHOS-Rh
[213343-64-7] 100mg
500mg
2g
45-0150 (-)-1,2-Bis((2R,5R)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium(I) trifluoromethanesulfonate, 98+%(R,R)-Et-DUPHOS-Rh
[136705-77-6] 100mg
500mg
2g 45-0151 (+)-1,2-Bis((2S,5S)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium(I) trifluoromethanesulfonate, 98+%(S,S)-Et-DUPHOS-Rh
[142184-30-3] 100mg
500mg
2g
45-0158 (-)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)benzene(cyclooctadiene)rhodium(I) tetrafluoroborate, 98+% (R,R)-Me-DUPHOS-Rh
[210057-23-1] 100mg
500mg
2g 45-0159 (+)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)benzene(cyclooctadiene)rhodium(I) tetrafluoroborate,98+%(S,S)-Me-DUPHOS-Rh
[205064-10-4] 100mg
500mg
2g
45-0160 (-)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)benzene(cyclooctadiene)rhodium(I) trifluoromethanesulfonate, 98+%(R,R)-Me-DUPHOS-Rh
[187682-63-9] 100mg
500mg
2g 45-0161 (+)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)benzene(cyclooctadiene)rhodium(I) trifluoromethanesulfonate, 98+%(S,S)-Me-DUPHOS-Rh
[136705-75-4] 100mg
500mg
2g
45-0168 (+)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)ethane(cyclooctadiene)rhodium(I) tetrafluoroborate, 98+% (R,R)-Me-BPE-Rh
[305818-67-1] 100mg
500mg
2g 45-0169 (-)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)ethane(cyclooctadiene)rhodium(I) tetrafluoroborate,98+%(S,S)-Me-BPE-Rh
[213343-65-8] 100mg
500mg
2g
45-0201 (-)-1,2-Bis((2R,5R)-2,5-diphenylphospholano)thane(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate,min.98%(R,R)-Ph-BPE-Rh
[528565-84-6] 100mg
500mg
2g 45-0202 (+)-1,2-Bis((2S,5S)-2,5-diphenylphospholano)ethane(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate,min.98%(S,S)-Ph-BPE-Rh 100mg
500mg
2g
45-0210 (+)-1,2-Bis((2R,5R)-2,5-di-i-propylphospholano)benzene(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate,min.98%(R,R)-i-Pr-DUPHOS-Rh
[569650-64-2] 100mg
500mg
2g 45-0211 (-)-1,2-Bis((2S,5S)-2,5-di-i-propylphospholano)benzene91,5-cyclooctadiene)rhodium(I) tetrafluoroborate,min.98%(S,S)-i-Pr-DUPHOS-Rh 100mg
500mg
2g


Exclusive world-wide license from DuPont for commercial applications in pharmaceuticals granted to Chirotech.
Research quantities available from Strem.

All items available for individual sale.